Nanoscope Advances Gene Therapy for Age-Related Vision Loss With FDA Filing and Phase 3 Plans
Nanoscope Therapeutics shares trial data on optogenetic therapies for macular degeneration and retinitis pigmentosa, with an FDA filing already accepted.
Summary
Nanoscope Therapeutics is presenting clinical results from two vision-restoring gene therapy programs at major ophthalmology meetings in Vienna. Their optogenetic therapy MOGENRY, targeting geographic atrophy — a late-stage form of age-related macular degeneration — has had a biologics license application accepted by the FDA after phase 2b/3 trial success. A second therapy, MCO-010, showed durable vision gains in retinitis pigmentosa patients over four years in an extension study, with a phase 3 trial planned for 2026. MOGENRY works without genetic testing, surgery, or repeat injections, making it practical for standard retina clinic settings. These advances represent meaningful progress in treating blinding age-related and inherited eye diseases that currently have very limited treatment options.
Detailed Summary
Age-related macular degeneration and retinitis pigmentosa are among the most common causes of severe vision loss in older adults, robbing people of independence and quality of life. Nanoscope Therapeutics is now presenting pivotal data from its gene therapy programs at two major ophthalmology conferences in Vienna, signaling that effective, long-lasting treatments for these conditions may be drawing closer to clinical reality.
The company's lead asset, MOGENRY (sonpiretigene isteparvovec), is an intravitreal optogenetic therapy designed for geographic atrophy, the advanced form of dry age-related macular degeneration. Following positive results from the RESTORE phase 2b/3 trial, the FDA has accepted and filed a biologics license application — a significant regulatory milestone suggesting the agency considers the submission complete and reviewable. Crucially, MOGENRY requires no genetic testing, no invasive surgery, and no repeat dosing, and it fits into existing retina office workflows, lowering barriers to widespread adoption.
The second program, MCO-010, targets retinitis pigmentosa, a degenerative inherited disease causing progressive night blindness and tunnel vision. Four-year data from the REMAIN extension study will be presented, showing lasting vision improvement — a notable result given the chronic, progressive nature of the disease. Promising phase 2 STARLIGHT data have already been reported, and a phase 3 registrational trial is planned for 2026.
For longevity-focused readers, preserving sensory function — especially vision — is directly tied to physical independence, cognitive engagement, and overall healthspan in later life. Vision loss accelerates social isolation, cognitive decline, and fall risk in older adults, making these therapies highly relevant beyond ophthalmology alone.
Caveats apply: the data are being presented at a congress, and full peer-reviewed publication of all results is pending. FDA approval is not guaranteed, and long-term safety across broader populations remains to be established.
Key Findings
- MOGENRY's FDA biologics license application has been accepted and filed following successful RESTORE phase 2b/3 trial results.
- MCO-010 showed lasting vision improvement over four years in retinitis pigmentosa patients in the REMAIN extension study.
- MOGENRY requires no genetic testing, surgery, or repeat dosing and fits standard retina clinic workflows.
- A phase 3 registrational trial for MCO-010 in retinitis pigmentosa is planned for 2026.
- Preserving vision in older adults is directly linked to maintaining independence, reducing fall risk, and slowing cognitive decline.
Methodology
This is a news report based on a company press release announcing conference presentations and regulatory milestones. The evidence basis includes phase 2b/3 trial results and a four-year extension study, but full peer-reviewed data have not yet been cited. Source is Longevity.Technology, a credible longevity-focused media outlet; independent verification against primary publications is advisable.
Study Limitations
All data are from company-sponsored trials reported via press release; independent peer-reviewed publication should be confirmed before drawing clinical conclusions. FDA acceptance of a filing does not guarantee approval, and long-term real-world safety data are not yet available. Phase 3 trial outcomes for MCO-010 remain pending.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: